HemoShear Therapeutics: Funding, Investors & Team (Oct 2026)
HemoShear Therapeutics is a biotech firm that specializes in identifying new targets in biology and developing medications for rare metabolic disorders in children. Our ultimate mission is to find drugs that can rescue the lives of children who are born with metabolic defects and are unable to sustain basic biochemical processes necessary for survival. Our unique technology allows us to replicate diseases by using liver tissue from children with genetic defects, study the disrupted biochemical processes, explore various drug strategies, and select drug candidates that have a high likelihood of succeeding in clinical trials. HemoShear distinguishes itself from other biotech companies through our exclusive models of human diseases and our capacity to recreate and understand intricate human biology. We strongly believe that no other company can rival our expertise in comprehending human hepatic, tumor, or vascular disease biology, and translating those insights into the development of safe and efficient drug treatments. Our commitment lies in comprehending disease biology and striving to discover effective drug treatments that enhance health outcomes and save lives. For further information, please visit www.hemoshear.com.
HemoShear Therapeutics has raised $43.5M across 2 funding rounds on record, the most recent an undisclosed round of $3.5M announced in Nov 2023.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
HemoShear Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2023.
HemoShear Therapeutics Funding Rounds
HemoShear Therapeutics raised $40.0M in a Series A announced in Feb 2021.
2.8 years later, an undisclosed round of $3.5M was announced in Nov 2023.
HemoShear Therapeutics Founders and Leadership Team
Contact details for the HemoShear Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →HemoShear Therapeutics Funding Compared to Other Biotechnology Startups
HemoShear Therapeutics' latest round of $3.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like HemoShear Therapeutics in Biotechnology and Charlottesville
Companies Similar to HemoShear Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
HemoShear Therapeutics Funding FAQs
What does HemoShear Therapeutics do?
HemoShear Therapeutics is a biotech firm that specializes in identifying new targets in biology and developing medications for rare metabolic disorders in children. Our ultimate mission is to find drugs that can rescue the lives of children who are born with metabolic defects and are unable to sustain basic biochemical processes necessary for survival. Our unique technology allows us to replicate diseases by using liver tissue from children with genetic defects, study the disrupted biochemical processes, explore various drug strategies, and select drug candidates that have a high likelihood of succeeding in clinical trials. HemoShear distinguishes itself from other biotech companies through our exclusive models of human diseases and our capacity to recreate and understand intricate human biology. We strongly believe that no other company can rival our expertise in comprehending human hepatic, tumor, or vascular disease biology, and translating those insights into the development of safe and efficient drug treatments. Our commitment lies in comprehending disease biology and striving to discover effective drug treatments that enhance health outcomes and save lives. For further information, please visit www.hemoshear.com.
How much funding has HemoShear Therapeutics raised?
HemoShear Therapeutics has raised $43.5M across 2 rounds on record. The most recent is an undisclosed round of $3.5M announced in Nov 2023.
When did HemoShear Therapeutics last raise funding?
HemoShear Therapeutics' most recent funding round on record is an undisclosed round of $3.5M, announced in Nov 2023.
Who is the CEO of HemoShear Therapeutics?
Brian R Wamhoff is listed as CEO at HemoShear Therapeutics.
Where is HemoShear Therapeutics headquartered?
HemoShear Therapeutics is based in Charlottesville, Virginia, United States.
How many employees does HemoShear Therapeutics have?
HemoShear Therapeutics is in the 11-50 employee band.
How does HemoShear Therapeutics' funding compare to other Biotechnology startups?
HemoShear Therapeutics' latest round of $3.5M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's HemoShear Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for HemoShear Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.